Brotizolam


Generic Medicine Info
Contraindications
Acute pulmonary insufficiency, sleep apnoea syndrome, myasthenia gravis, psychoses, acute narrow-angle glaucoma. Severe hepatic impairment. Pregnancy and lactation.
Special Precautions
Patient in whom a drop in BP might lead to cardiac complications; chronic pulmonary insufficiency. Prolonged use may cause dependence. Avoid abrupt withdrawal. Renal and mild to moderate hepatic impairment. Patient Counselling May impair ability to drive or operate machinery.
Adverse Reactions
Paradoxical reactions (e.g. acute hyperexcitability, anxiety, hallucinations, increased muscle spasticity, rage, insomnia, sleep disturbances and stimulation); drowsiness, fatigue, ataxia; sedation and sleepiness, depression, lethargy, apathy, hypoactivity, lightheadedness, disorientation, restlessness, confusion, delirium, headache, slurred speech, dysarthria, syncope, vertigo, tinnitus, dizziness, nervousness, vivid dreams, psychomotor retardation; constipation, diarrhoea, dry mouth, nausea, vomiting, increased salivation; incontinence, dysuria, enuresis, changes in libido, urinary retention, menstrual irregularities; bradycardia, tachycardia, HTN, hypotension, palpitations; visual disturbances, diplopia; urticaria, pruritus, skin rash, dermatitis; hepatic dysfunction (e.g. hepatitis, jaundice), blood dyscrasias (e.g. agranulocytosis, anaemia, thrombocytopenia, eosinophilia).
Drug Interactions
May potentiate the effect of centrally-acting drugs (e.g. neuroleptics, tranquilisers, antidepressants, hypnotics, antiepileptics, antihistamines, analgesics and anaesth). May increase the effect of muscle relaxants. Increased effect w/ CYP3A4 inhibitors (e.g. itraconazole, ketoconazole). Decreased effect w/ CYP3A4 inducers (e.g. carbamazepine, efavirenz).
ATC Classification
N05CD09 - brotizolam ; Belongs to the class of benzodiazepine derivatives. Used as hypnotics and sedatives.
Disclaimer: This information is independently developed by CIMS based on brotizolam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in